Efeitos da formulação mucoadesiva de Bidens pilosa L. (Asteraceae) e Curcuma longa L. (Zingiberaceae) no tratamento da mucosite intestinal

• Autor(a) principal: Bastos, Carla Caroline Cunha
• Data de Publicação: 2014
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/00130000007gt
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/4114
• topic: Mucosite intestinal; Bidens pilosa L; Curcuma longa L; Intestinal mucositis; Bidens pilosa L; Curcuma longa L; Mucoadhesion; FARMACOLOGIA::FARMACOLOGIA CLINICA

Intestinal mucositis is a limiting factor in anticancer therapies by causing gastrointestinal cell destruction reaching the majority of patients undergoing chemotherapy/radiotherapy and is often responsible for treatment discontinuation. Although several studies have already been conducted to treat this disease, there are still no universally accepted and standardized protocols of treatment. Plant species with anti-inflammatory and antioxidant properties have been considered for the treatment of mucositis, among them Bidens pilosa L. (BP) (Asteraceae) and Curcuma longa L. (CL) (Zingiberaceae). In this study, the effects of a formulation containing plant extracts of Bidens pilosa L. (BP) and Curcuma longa L. (CL), both with pharmaceutical technology of mucoadhesion in mice intestinal mucositis induced by 5-fluoruoacil (5-FU) were studied. This formulation was administered orally (gavage) for 6 days in each group of mice at doses of 75mg/kg + BP 3.75 mg / kg CL 100 mg / kg BP + 7.5 mg / kg or 125 mg CL / BP kg + 15 mg / kg CL. The treatment with the formulations occurred during six days, and in parallel with mucositis induction was performed with 5-FU (200 mg / kg, intraperitoneally) from day 4 to day 6. On day 7, the mice were euthanized and the duodenal portion of the intestine of each animal was extracted to perform the histomorphometry technique. From this analysis, the dose of 125 mg/kg mucoadhesive formulation showed best effectiveness results and was then chosen for the realization of the other tests: histopathology analysis, expression of Bax, Bcl-2, p53 and Ki-67 analysis via immunohistochemistry technique; analysis of the activity of myeloperoxidase (MPO) enzyme, and determination of malondialdehyde (MDA) levels. Furthermore, analysis of weight change and hematologic parameters were performed. To prove safety of the formulation, an oral toxicity test of mucoadhesive formulation, and effect evaluation of the plant extracts on the animals’intestine not submitted to mucositis were performed. The mucoadhesive formulation was able to assuage the histopathological damage caused by 5-FU; reduced weight loss, reduced levels of MPO and MDA; stimulated cell proliferation by increasing the expression of Ki-67; besides decreasing apoptosis observed by analyzing the expression of Bax and Bcl-2. The formulation at a dose of 2000mg/kg showed no signs of toxicity. It can be concluded that the formulation under study exerts preventive and/or therapeutic effects to intestinal mucositis with potential to be used with associated to anticancer treatment.